RPRX vs VLTO · P/E 15, rev $1.30B vs P/E 29, rev $5.50B
Royalty Pharma Plc (RPRX) versus Veralto Corporation (VLTO) — a side-by-side from cached financials, not a winner call.
Royalty Pharma Plc (RPRX) is a biotechnology company listed on US.
Veralto Corporation (VLTO) is a pollution & treatment controls company listed on US.
Latest reported RPRX revenue for 2026-06-30 was $1.30B. Net income was $312.6M. RPRX currently screens at market cap $20.45B and trailing P/E 14.8.
Latest reported VLTO revenue for 2025-12-31 was $5.50B. Net income was $940.0M. Revenue was up 6.0% from 2024-12-31 to 2025-12-31. VLTO currently screens at market cap $25.26B and trailing P/E 29.1.
RPRX currently screens at market cap $20.45B and trailing P/E 14.8. VLTO currently screens at market cap $25.26B and trailing P/E 29.1.
Not investment advice. Open the RPRX and VLTO stock pages for the full models.
Not investment advice.